To Get more Insights,  Request A Free Sample 

Market Dynamics 

Driver: Patent Expirations of Blockbuster Drugs Fueling Generic Production

The expiration of patents for blockbuster drugs is a primary driver of the generic pharmaceuticals contract manufacturing market. In 2024, over 150 major drug patents are set to expire, creating a significant opportunity for generic manufacturers. Drugs like Humira, which lost its patent exclusivity, have seen a surge in generic versions, with over 20 biosimilars already in the market. This has led to increased demand for contract manufacturing services, particularly for complex biologics. Companies like Teva Pharmaceuticals are expanding their capacity to meet this demand, with Teva investing $200 million in new biologics facilities. The expiration of patents for cancer drugs like Keytruda is also driving growth, with over 10 generic versions in development. This trend is expected to continue, with over 300 drug patents set to expire by 2030.

The shift towards cost-effective healthcare solutions is further accelerating this driver in the generic pharmaceuticals contract manufacturing market. Governments and healthcare providers are increasingly turning to generics to reduce costs, particularly in oncology and cardiovascular care. For instance, the generic version of the cancer drug Rituxan has seen production of over 5 million doses in 2024. The demand for generics is particularly strong in emerging markets, where access to affordable healthcare is critical. In India alone, the production of generic drugs increased by 15% last year, driven by the expiration of patents for drugs like Lipitor. As more blockbuster drugs lose their exclusivity, the demand for contract manufacturing services is expected to grow exponentially.

Trend: Rising Demand for Biologics and Biosimilars in Generic Manufacturing

The growing demand for biologics and biosimilars is reshaping the generic pharmaceuticals contract manufacturing market. In 2024, over 70 biosimilar products are in development globally, with a focus on oncology and autoimmune diseases. Drugs like Humira and Rituxan have seen a significant increase in biosimilar production, with over 20 biosimilars for Humira alone. This trend is driven by the need for affordable alternatives to expensive biologics, particularly in cancer treatment. Companies like Lonza are leading the way in biologics manufacturing, with over $500 million invested in new facilities in the past two years. The production of biosimilars is expected to double by 2026, driven by advancements in biotechnology and regulatory approvals.

The shift towards biologics in the generic pharmaceuticals contract manufacturing market is also driven by the increasing prevalence of chronic diseases such as cancer and diabetes. For instance, the production of biosimilar insulin has increased by 25% in 2024, driven by the growing demand for diabetes treatment. The adoption of advanced manufacturing technologies, such as continuous manufacturing, is also supporting this trend. Catalent, for example, has invested $350 million in new facilities to enhance biologics production. As the demand for biologics and biosimilars continues to grow, contract manufacturers are expected to play a critical role in meeting this demand, particularly in emerging markets where access to affordable biologics is limited.

Challenge: Complexity in Manufacturing Biologics and Biosimilars

The complexity of manufacturing biologics and biosimilars is a significant challenge in the generic pharmaceuticals contract manufacturing market. Unlike small-molecule drugs, biologics require highly specialized facilities and expertise, which can be costly and time-consuming to develop. In 2024, over 50% of biologics manufacturing facilities reported delays in production due to technical challenges. For instance, the production of biosimilar versions of Humira has faced significant hurdles, with over 10 biosimilars experiencing delays in regulatory approval. This complexity is further compounded by the need for stringent quality control measures, which can increase production costs by up to 30%.

The regulatory landscape for biologics and biosimilars is also more complex, with over 40% of biosimilar applications facing delays in approval in 2024. Companies in the generic pharmaceuticals contract manufacturing market like Lonza and Catalent are investing heavily in advanced manufacturing technologies to address these challenges, with over $1 billion invested in new facilities in the past two years. Despite these efforts, the high cost of biologics manufacturing remains a significant barrier, particularly for smaller contract manufacturers. The production of biosimilar insulin, for example, requires specialized facilities that can cost up to $200 million to build. As the demand for biologics and biosimilars continues to grow, overcoming these manufacturing challenges will be critical for the success of contract manufacturers in this market.

Segmental Analysis 

By Product Type 

APIs hold over 58% of the generic pharmaceuticals contract manufacturing market due to their critical role in drug formulation. The top seven APIs driving demand include metformin, amoxicillin, paracetamol, ibuprofen, omeprazole, atorvastatin, and losartan. Metformin, used for diabetes management, sees annual production exceeding 50,000 tons globally. Amoxicillin, a widely used antibiotic, has a global demand of over 30,000 tons annually. The cost efficiency of API production, particularly in countries like India and China, where labor and raw material costs are lower, has further boosted this segment. The global API market is expected to grow by 6.8% annually, driven by increasing demand for affordable medications and the expansion of generic drug production.

The API’s growth in the generic pharmaceuticals contract manufacturing market is further driven by the increasing complexity of drug formulations, which require high-quality APIs to ensure efficacy and safety. For example, the production of APIs for biologics, such as monoclonal antibodies, has seen a 15% annual growth rate due to their use in treating diseases like cancer and autoimmune disorders. The global API market is also benefiting from the rise of contract development and manufacturing organizations (CDMOs), which produce over 40% of APIs worldwide. The demand for APIs is further fueled by the need for continuous supply chain resilience, as seen during the COVID-19 pandemic, when API production for drugs like remdesivir surged by 200%. The increasing focus on green chemistry and sustainable API production methods is also shaping the market, with companies investing over $2 billion in eco-friendly manufacturing processes.

By Route of Administration 

Over 62% of drugs produced in the generic pharmaceuticals contract manufacturing market are administered orally, primarily due to patient convenience and cost-effectiveness. Oral medications, such as tablets and capsules, are easier to manufacture and distribute, with production costs 40% lower than injectables. The global oral solid dosage market is projected to grow by 6.5% annually, driven by the rising demand for chronic disease treatments. Oral drugs also have higher patient compliance rates, with studies showing 70% of patients prefer oral medications over other routes. The affordability of oral generics, often priced 80% lower than branded counterparts, further drives market revenue. The oral route’s dominance is also supported by advancements in drug delivery technologies, such as controlled-release formulations.

The oral route’s dominance in the generic pharmaceuticals contract manufacturing market is further reinforced by advancements in formulation technologies, such as nanotechnology and lipid-based delivery systems, which enhance drug bioavailability. For instance, the global market for oral lipid-based drug delivery systems is growing at a rate of 12% annually, driven by their ability to improve the absorption of poorly soluble drugs. The oral route also benefits from the increasing popularity of over-the-counter (OTC) medications, which account for 60% of all drug sales globally. The convenience of oral medications is particularly important in pediatric and geriatric populations, where compliance rates are 30% higher compared to other routes. The global market for pediatric oral medications is expected to grow by 8% annually, driven by the rising prevalence of chronic diseases in children. Additionally, the oral route’s cost-effectiveness is further enhanced by the ability to produce large batches, with a single production line capable of manufacturing over 1 million tablets per day.

By Application 

Oncology is the most dominant application in the generic pharmaceuticals contract manufacturing market, driven by the high cost of cancer treatments and the increasing prevalence of cancer globally. The global oncology drug market is valued at $167 billion, with generics saving up to 60% on treatment costs. Generic versions of drugs like paclitaxel and docetaxel have reduced the cost of chemotherapy by $1.2 billion annually. The rising incidence of cancer, with 19.3 million new cases reported globally in 2023, has further fueled demand for affordable oncology drugs. Generic manufacturers are leveraging economies of scale to produce high-quality, low-cost cancer treatments, making them accessible to a broader patient population. The oncology segment is expected to grow by 8.3% annually, driven by increasing healthcare expenditure and the need for cost-effective cancer therapies.

The oncology segment’s growth is further supported by the increasing adoption of targeted therapies and immunotherapies, which are often produced as generics to reduce costs. For example, generic versions of imatinib, used to treat chronic myeloid leukemia, have saved healthcare systems $1.5 billion annually. The global market for oncology generics is also driven by the rising incidence of rare cancers, which account for 22% of all cancer cases. The development of biosimilars for oncology drugs in the generic pharmaceuticals contract manufacturing market, such as rituximab, has further expanded the market, with biosimilars saving $3 billion annually in the U.S. alone. The increasing focus on precision medicine has also led to the development of niche oncology generics, catering to specific genetic mutations. The global oncology generics market is expected to grow by 9% annually, driven by the need for affordable cancer treatments and the increasing availability of generic versions of biologics.

By Drug Type 

Branded generics dominate the generic pharmaceuticals contract manufacturing market, generating over 63% of market revenue. This demand is driven by their ability to offer high-quality, cost-effective alternatives to branded drugs, often at 30-50% lower prices. The expiration of patents for blockbuster drugs, such as Lipitor and Crestor, has opened opportunities for branded generics, which combine the trust of a brand with the affordability of generics. Governments worldwide are promoting generic usage to reduce healthcare costs, with initiatives like the U.S. Medicare Part D program saving $2.6 billion annually through generic substitution. Additionally, the rising prevalence of chronic diseases, such as diabetes and hypertension, has fueled demand for affordable treatments. The global branded generics market is projected to grow by 7.2% annually, driven by increasing healthcare access in emerging markets like India and China.

The demand for branded generics in the generic pharmaceuticals contract manufacturing market is further amplified by their ability to address unmet medical needs in emerging markets, where access to expensive branded drugs is limited. For instance, in India, branded generics account for 70% of the pharmaceutical market, with over 1.5 billion units sold annually. The global branded generics market is also supported by regulatory incentives, such as the U.S. FDA’s Generic Drug User Fee Amendments (GDUFA), which have reduced approval times by 60%. Additionally, the increasing adoption of biosimilars, which are often marketed as branded generics, has expanded the market. Biosimilars like trastuzumab have saved healthcare systems $1.8 billion annually in the U.S. alone. The growing focus on personalized medicine has also led to the development of niche branded generics, catering to specific patient populations. This trend is expected to continue, with the global branded generics market projected to reach $500 billion by 2030.

 To Understand More About this Research:  Request A Free Sample 

Regional Analysis 

Asia Pacific is the largest generic pharmaceuticals contract manufacturing market, contributing over $30 billion in revenue. The region’s dominance is driven by low production costs, skilled labor, and robust infrastructure. India, China, and South Korea are the top three countries in terms of production, consumption, and import-export activities. India alone accounts for 20% of global generic drug exports, with annual production exceeding 60,000 tons. China’s API production capacity, at over 100,000 tons annually, further strengthens the region’s position. The Asia Pacific market is projected to grow by 7.5% annually, driven by increasing healthcare access and government initiatives to promote generic drug usage. The region’s cost advantage, with production costs 50% lower than in Western markets, has made it a global hub for generic manufacturing. The expansion of pharmaceutical infrastructure and increasing investments in R&D are also shaping the regional market’s growth trajectory.

The Asia Pacific region’s dominance in generic pharmaceuticals contract manufacturing market is further bolstered by its strategic geographic location, which facilitates easy access to global markets. For instance, India’s pharmaceutical exports reached $25 billion in 2023, with over 50% of its production destined for the U.S. and Europe. China’s API production capacity, which exceeds 100,000 tons annually, has made it a global leader in raw material supply, with over 40% of the world’s APIs sourced from the country. South Korea’s focus on biotechnology and advanced manufacturing techniques has also contributed to the region’s growth, with the country’s pharmaceutical exports growing by 15% annually. The region’s cost advantage is further enhanced by government incentives, such as tax breaks and subsidies, which have attracted over $5 billion in foreign investments in the past five years. The increasing focus on quality and regulatory compliance has also strengthened the region’s position, with over 80% of manufacturing facilities in India and China meeting international standards. The Asia Pacific market is expected to continue its growth trajectory, driven by the increasing demand for affordable medications and the region’s ability to scale production rapidly.

Top Companies in the Generic Pharmaceuticals Contract Manufacturing Market

• Acme Generics Pvt Ltd.
• Ajinomoto Health Nutrition
• Alcami Corp., Inc.
• Aurobindo Pharma
• Cambrex Corp.
• Catalent
• Curia Global, Inc.
• Dr. Reddy's Laboratories
• Fresenius Kabi
• Hetero Labs
• Jubilant Generics Ltd.
• Lonza
• Metrics Contract Services
• Pfizer Centre One
• Recipharm AB
• Siegfried Holding AG
• Syngene International Ltd.
• Thermo Fisher Scientific
• Other Prominent Players

Market Segmentation Overview:

By Product

• API
• Drug Product

By Route of Administration

• Oral
• Parenteral
• Topical
• Others

By Drug Type 

• Branded Generics
• Unbranded Generics

By Application

• Neurology
• Oncology
• Immunology
• Antidiabetic
• Anticoagulants
• Cardiovascular
• Respiratory
• Pain
• HIV antivirals
• Others

By Region 

• North America
  • The USA
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America